Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis

Fig. 4

Gene and pathway signatures between abatacept and placebo groups at baseline. a Blue identifiers are improvers, black identifiers are placebos and orange identifier is non-improver; b 1,640 genes had significant differential expression at baseline between abatacept and placebo groups (p < 0.05); c 15 GSEA pathways were significantly differentially expressed at baseline between abatacept and placebo groups (FDR <10 %)

Back to article page